Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontuxizumab in metastatic melanoma
NCT01335009Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2011
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of ontuxizumab in melanoma (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Progression-Free Survival at 24 weeks. Started May 2011; status: completed.
02
Drugs
ontuxizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01335009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01335009.